Survivin Archives

Tag: Survivin

Survivin is the smallest member of the Inhibitor of apoptosis (IAP) family of proteins, involved in inhibition of apoptosis and regulation of cell cycle. These functional attributes make Survivin a unique protein exhibiting divergent functions i.e. regulating cell proliferation and cell death. Expression pattern of Survivin is also distinctive; it is prominently expressed during embryonal development, absent in most normal, terminally differentiated tissues but upregulated in a variety of human cancers. Expression of Survivin in tumours correlates with not only inhibition of apoptosis and a decreased rate of cell death, but also resistance to chemotherapy and aggressiveness of tumours. Therefore, Survivin is an important target for cancer vaccines and therapeutics

26 Nov 2024

By Ronny Allan

0 Comments

Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Tumors

Clinical Trials and ResearchClinical trial, SurVaxM, Survivin, Temozolomide (Temodal)

What are cancer vaccines?I remember seeing a comment by a NET Specialist on twitter saying, "We need vaccines". This was in response to a tweet from another NET Specialist reporting dismal data from an immunotherapy drug for Neuroendocrine Carcinomas. In 2020/2021, the word vaccine has been used a lot, but this specialist was not inferring anti-viral treatment, he was talking about "cancer vaccines", an emerging discipline in science where vaccines act as an immunostimulant to treat cancer. This prompted me to look around and found this trial which may be of interest to you. However, before anyone gets too excited,…

22 May 2021

By Ronny Allan

2 Comments

Clinical Trial Phase 2: Survivin Long Peptide Vaccine (SurVaxM) with Temozolomide in Treating Patients With Grade 3 Neuroendocrine Neoplasms

Clinical Trials and ResearchCancer vaccine, Glioma, Gliomablastoma, Metastatic Neuroendocrine Cancer, Multiple myeloma, SurVaxM, Survivin

Update 5th May 2026. Biotechnology company MimiVax Inc. and Roswell Park Comprehensive Cancer Center today jointly announced the launch of a phase 2 clinical trial (NCT06202066) evaluating SurVaxM in combination with temozolomide in patients with progressing neuroendocrine tumours, also known as NETs. The study is being conducted at Roswell Park in Buffalo, New York, under the direction of principal investigator Dr. Jasmeet Kaur.This trial has changed course. It started in 2021 as a phase 1 trial for NETs. A separate trial then added Temozolomide as a combo treatment. Then Phase 2 of the clinical trial gathered all the data and the original trial continues with the…